Spectrum Pharmaceuticals reported $12.86M in Stock for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Stock including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported 355.8M in Outstanding Shares in July of 2023. Data for Spectrum Pharmaceuticals | SPPI - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $366.5M in Market Capitalization this July of 2023, considering the latest stock price and the number of outstanding shares.Data for Spectrum Pharmaceuticals | SPPI - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last July in 2025.

AI-powered price forecasts for SPPI stock across different timeframes including weekly, monthly, yearly, and multi-year predictions.

Spectrum Pharmaceuticals reported $28.84M in Loan Capital for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Loan Capital including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $107.68M in Assets for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Assets including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $-5007000 in Net Income for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Net Income including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $1.06M in Cost of Sales for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last July in 2025.

VIQ Solutions (VQS) Shares of VQS stock have been in recovery mode since last quarter. That was when the AI-driven tech company saw its stock price plummet after reporting earnings. Fast-forward a few months, and the VIQ Solutions stock price has climbed by more than 100%, with daily volumes increasing this month. There could be a few things in play for VQS stock. As we know, ChatGPT and AI stocks are gaining plenty of speculative interest right now. The massive surge of attention on machine learning has prompted a breakout in plenty of companies with exposure to the space. VIQ provides digital voice and video capture technology and transcription services. Late last month, based on the data provided by the short interest api, the company boosted its AI workflows with a new automatic speech recognition platform to increase accuracy in multi-speaker environments. “Our clients see the value in our ability to implement our integrated solutions and service offerings to transform and analyze digital content and securely generate accurate, actionable information,” said Vahram Sukyas, Chief Technology Officer, VIQ Solutions. This week VIQ expanded its global technology footprint and signed a multi-year contract with Transcription Hub, a transcription services company, to provide internal and commercial workflow solutions to transcription services organizations in India. The platform is designed to decrease turnaround time and yield higher transcription accuracy. Imperial Petroleum Inc. (IMPP) With China reopening from COVID lockdowns (finally), energy stocks are coming back into focus. Gas prices are climbing thanks to a mild winter as well. Imperial Petroleum has experienced its share of energy industry speculation and momentum-fueled moves over the last year. In fact, at one point in 2022, share prices reached highs of over $9. Solid earnings from its last quarter have begun coming back into the picture now, as earnings season is well underway. The third quarter saw Imperial report an Earnings Per Share of 8 cents compared to a loss of 3 cents from a year ago. The company also saw its sales explode. The company did just under $5.8 million in sales for the third quarter of 2021. The 2022 Q3 figures were more than 630% higher at $42.6 million. CEO Harry Vafias also highlighted several key points of the third quarter’s performance. He said, “As a result of having acquired six vessels in the course of ten months, we generated net income of $15.5 million in a single quarter which is 15,400% higher than our profit in Q2 22’ and equivalent to 23% of our current market capitalization; We incurred moderate debt during the quarter, maintaining a healthy capital structure with $42.3 million of debt while preserving a free cash balance available for further fleet expansion of about $92 million. Given the strong market fundamentals and the promising charter rate environment and by taking advantage of our efficient management of our expanded fleet, we believe that we will achieve strong results and generate significant cash flow going forward.” With a more bullish tone in energy, it will be interesting to see how the company’s next round of earnings compares. Spectrum Pharmaceuticals (SPPI) AI and chatGPT stocks aren’t the only things getting attention in the stock market today. “Old standbys” like biotech penny stocks remain a hot topic. They usually become a source of speculative trading trends due to ongoing trials that can make more break certain companies. Spectrum Pharmaceuticals, one of the best value stocks, has performed well this year, having risen over 100% since the beginning of January. The company develops targeted oncology treatment platforms. This week Spectrum announced receipt of a permanent J-code (J1449) for its ROLVEDON injection from the U.S. Centers for Medicare & Medicaid Services. J-codes are reimbursement codes used by commercial insurers, including Medicare, Medicare Advantage, and other government payers, for certain drugs. “A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023, and ROLVEDON’S inclusion in the National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) announced on December 6, 2022, are key elements in establishing brand awareness and building customer confidence in our novel product,” said CEO Tom Riga. Wearable Devices Ltd. (WLDS) We discussed WLDS stock toward the end of 2022 and other low float penny stocks. Wearable Devices, as one of the best growth stocks for any investors, is developing non-invasive neural input interface technology via wearables, including wristbands. Wearers can control digital devices using things like subtle finger movement to do so. This week the company announced that it received approval for a $900,000 grant budget for developing a manufacturing process of its AI-based neural interface, the Mudra Band. CEO Asher Dahan...

Spectrum Pharmaceuticals reported $15.61M in Sales Revenues for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $20.48M in Operating Expenses for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $105.38M in Current Assets for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Current Assets including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $-4870000 in Operating Profit for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Operating Profit including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $38.88M in Current Liabilities for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $14M in Selling and Administration Expenses for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported 14.55M in Gross Profit on Sales for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last June in 2025.

Spectrum Pharmaceuticals reported $35M in Trade Creditors for its fiscal quarter ending in September of 2022. Data for Spectrum Pharmaceuticals | SPPI - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported 86 in Employees for its fiscal year ending in December of 2022. Data for Spectrum Pharmaceuticals | SPPI - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported 943K in Interest Expense on Debt for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Spectrum Pharmaceuticals reported $205K in Ordinary Share Capital for its fiscal quarter ending in March of 2023. Data for Spectrum Pharmaceuticals | SPPI - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last July in 2025.